$80 million
total funding
Lindus Therapeutics
Next-generation drug development
Lindus advances portfolios of in-licensed assets through our integrated trial platform, collaborating with biotech and pharma to take medicines further, faster.
45+
completed trials across broad therapeutic areas
120
team size across the US and Europe
82%
of Lindus trials completed enrollment on or ahead of timeline
[1]
[1] Measured against all 28 trials that completed enrollment within the past 3 years, where Lindus was responsible for enrollment.
About us
Leveraging our trial execution capability
to build an internal asset portfolio
Lindus was originally founded as a technology-first clinical research organization. We have now expanded into asset development, leveraging our trial delivery capability. Lindus runs faster, higher quality clinical trials using technology to automate manual processes, recruit patients directly, and provide real-time access to data.
Why Lindus
A partner that can execute on what
you've built
01
Proven in-house trial execution
A track record of delivering trials on time and on budget across 45+ completed programs. Your asset is developed by the same team that designs and executes it. No external CRO layer, no handoff, no misaligned incentives.
02
Faster timeline to readout
Centralized patient enrollment infrastructure combines AI-powered EHR querying, digital pre-screening, and patient concierge. This reduces screen failures and compresses enrollment timelines. Our trial platform enables faster close-out and analysis.
03
Optimized trial designs
Our technology platform and international footprint enable trial designs that aren't practical with standard biopharma partners: multi-country trials, multi-indication programs, and adaptive approaches built to the asset.
Team and advisors
Leadership with deep operational and
scientific expertise
Leadership
.jpeg)
Meri Beckwith
Co-Founder and CEO
Former life sciences and healthtech venture capital investor. Co-founded Lindus after seeing CROs repeatedly fail to deliver trials on time and on budget. MSc Biology, University of Oxford.
.jpeg)
Michael Young
Co-Founder
Previously Special Adviser to the UK Prime Minister on life sciences. Before government, advised healthcare clients at McKinsey & Company and L.E.K. Consulting.
Dr. Luke Twelves
CMO
Physician with nearly three decades of clinical and leadership experience. Former CEO of Omnes Healthcare. Trained at Oxford, Cambridge, and Durham (MBA).
.png)
Sean Sheppard
VP Corporate Development
Previously Director of BD and Investments at AtaiBeckley, leading licensing, M&A and equity deals across its clinical-stage neuroscience portfolio. Began his career at L.E.K. Consulting and holds Natural Sciences degrees from the University of Cambridge.
Gemma Harrison
CPTO
Gemma leads R&D of Citrus, Lindus’ AI-assisted operating system. She is a technology executive who has spent her career building and scaling engineering teams. Before Lindus she spent three years as a Principal Software Engineering Manager at Microsoft, leading teams of up to 30 engineers on Telecoms products in Azure. Prior to that she spent 23 years at Metaswitch Networks, advancing from Software Engineer to Senior Software Engineering Manager. She holds a BA in Mathematics and a Diploma in Computer Science from the University of Cambridge, and is an active advocate for women in technology.
Advisors
Dr. Robert Langer
Strategic Advisor
Co-founder of Moderna and 40+ biopharma companies. Institute Professor at MIT. Holds 1,400+ patents and is one of three living individuals to receive both the US National Medal of Science and the National Medal of Technology and Innovation.
Dr. Tim Garnett
Strategic Advisor
Former Chief Medical Officer and SVP at Eli Lilly (2008-2021). Oversaw regulatory affairs, patient safety, and global clinical development across the US, Europe, China, and Japan.
Dr. Alessandro Falcone
Strategic Advisor
Regional Head of JLABS Singapore for Johnson & Johnson. Previously Executive Director of Breast Cancer Oncology R&D Clinical Development Strategy at AstraZeneca, leading programs for Enhertu, Lynparza, and Imfinzi.
Our approach
Deal structures that work for both sides
Lindus structures deals to work for our partners from signing through clinical and commercial milestones. Terms are designed around what fits the asset and your goals.
We are flexible about deal types, whether that means exclusive or non-exclusive licenses, territory splits, option agreements, joint ventures, or co-development.
Geographic footprint
With a full time team of over 120, our footprint covers North America and Western Europe, with capability to enroll sites & patients in select additional countries.
Core presence
Integrated partnership
